妊娠期使用SSRI与母亲抑郁:全国出生队列研究
芬兰1996—2018年全国登记数据纳入1272587例单胎活产,比较妊娠期购买≥2次SSRI者(19020例)、有抑郁诊断但未用抗抑郁药者(19625例)及孕前停用SSRI者(3145例)。校正抑郁严重度并做同胞比较后,SSRI使用与妊娠期糖尿病风险升高相关,新生儿适应不良相关结局风险升高,但早产和低出生体重风险降低。
要点
- SSRI使用与妊娠期糖尿病风险升高相关,需加强孕期血糖监测。
- SSRI暴露增加5分钟Apgar低分、呼吸问题和新生儿病房治疗风险。
- SSRI可能降低早产和低出生体重风险,但新生儿适应不良风险仍升高。
核心结论
- 妊娠期使用SSRI在校正母亲抑郁后仍影响新生儿健康,增加新生儿适应延迟相关症状,但可能降低早产风险。
- 观察到的妊娠期糖尿病风险升高需进一步研究。
研究设计与样本
- 基于芬兰国家登记的全国性出生队列研究,纳入1996—2018年1272587例单胎活产。
- 暴露组为妊娠期购买≥2次SSRI者(N=19020),对照为有抑郁诊断但未用抗抑郁药者(N=19625)及孕前停用SSRI者(n=3145)。
- 分析校正多项抑郁严重度指标,并进行同胞比较。
主要发现
- 校正混杂后,SSRI使用与妊娠期糖尿病风险升高相关(OR 1.14;95%CI 1.07-1.22)。
- SSRI使用与剖宫产、晚期早产(32-36+6周)、极早产(<32周)、小于胎龄儿及低/极低出生体重风险降低相关。
- SSRI暴露婴儿5分钟Apgar评分<7风险升高(OR 2.02;95%CI 1.78-2.30),呼吸问题风险升高(OR 1.61;95%CI 1.48-1.75),新生儿病房治疗风险升高(OR 1.23;95%CI 1.16-1.31)。
- 孕晚期暴露进一步增加5分钟Apgar低分风险(OR 3.44;95%CI 2.93-4.04)。
- 与孕前停用SSRI者相比,SSRI使用与晚期早产(OR 0.83;95%CI 0.70-0.999)和低出生体重(OR 0.78;95%CI 0.64-0.96)风险降低相关,新生儿风险仍升高。
关键数值与推荐
- 妊娠期SSRI使用与妊娠期糖尿病相关(OR 1.14;95%CI 1.07-1.22);校正抑郁严重度后仍持续(OR 1.20;95%CI 1.09-1.32)。
- 5分钟Apgar评分<7的OR 2.02(95%CI 1.78-2.30),呼吸问题OR 1.61(95%CI 1.48-1.75),新生儿病房治疗OR 1.23(95%CI 1.16-1.31)。
- 孕晚期暴露与5分钟Apgar低分相关OR 3.44(95%CI 2.93-4.04)。
- 与孕前停用SSRI者相比,晚期早产OR 0.83(95%CI 0.70-0.999),低出生体重OR 0.78(95%CI 0.64-0.96)。
临床怎么用
- 对有抑郁病史的孕妇评估SSRI使用时,应兼顾母亲精神健康与新生儿适应不良风险。
- SSRI暴露孕妇应加强妊娠期糖尿病筛查与血糖管理。
- 分娩前应告知孕晚期SSRI暴露的新生儿可能需要Apgar评分和呼吸监测及新生儿病房支持。
局限性
- 为观察性登记研究,尽管校正抑郁严重度并做同胞比较,仍可能存在残余混杂。
- 妊娠期糖尿病风险升高的机制与临床意义需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Maternal underlying depression may confound previously reported associations between selective serotonin reuptake inhibitor (SSRI) use and adverse pregnancy and neonatal outcomes. OBJECTIVE: To determine whether SSRI use during pregnancy is associated with an increased risk of pregnancy and neonatal complications after adjusting for indicators of maternal depression severity. STUDY DESIGN: This population-based birth cohort study used data from national registers in Finland and included 1272,587 singleton live births from 1996 to 2018. Pregnancy outcome of women with two or more SSRI purchases during pregnancy (N=19,020) were compared to women with a diagnosis of depression but no antidepressant use (N=19,625), and women who discontinued SSRIs before pregnancy (n=3145). Analyses included adjustment for several indicators of depression severity and within-family sibling comparisons. RESULTS: After adjusting for confounders and comparing to women with depression who did not use antidepressants, maternal SSRI use was associated with an increased risk of gestational diabetes (OR 1.14; 95% CI 1.07-1.22), while the risk of cesarean section (CS), late (32-36+6 weeks' gestation) and very preterm birth (<32 weeks' gestation), small for gestational age, and low and very low birth weight was lower. Among SSRI-exposed infants, risk of a low (<7) 5-minute Apgar score (OR 2.02; 95% CI 1.78-2.30), breathing problems (OR 1.61; 95% CI 1.48-1.75), and neonatal care unit (NCU) treatment (OR 1.23; 95% CI 1.16-1.31) was higher, whereas the risk of hospital stay at 7 days and major congenital anomalies was lower. Third-trimester exposure further increased the risk of a low 5-minute Apgar score (OR 3.44; 95% CI 2.93-4.04). After adjustment for indicators of depression severity, the increased risk of gestational diabetes persisted (OR 1.20; 95% CI 1.09-1.32), as did the lower risk of CS, very preterm birth, and low and very low birth weight, and the risks of a low 5-minute Apgar score, breathing problems, and NCU treatment remained higher. Compared to women who discontinued SSRI use before pregnancy, SSRI use was associated with lower risks of late preterm birth and low birth weight (OR 0.83; 95% CI 0.70-0.999 and OR 0.78; 95% CI 0.64-0.96, respectively), while the neonatal risks described above remained elevated. In the sibling-pair analysis, SSRI use was associated with an increased risk of gestational diabetes and neonatal complications other than malformations, including an increased risk of needing hospital stay at 7 days of age. CONCLUSION: SSRI use during pregnancy affects neonatal health beyond maternal depression by increasing symptoms related to delayed neonatal adaptation, although it may reduce the risk of preterm birth. The observed increase in the risk of gestational diabetes warrants further study. VIDEO ABSTRACT.
引用
- Malm H, Brown AS, Cheslack-Postava K, et al. Selective serotonin reuptake inhibitor use during pregnancy and maternal depression-a nationwide birth cohort study on risks to the mother and the newborn. Am J Obstet Gynecol MFM. 2026. PMID: 41651031. doi:10.1016/j.ajogmf.2026.101910
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。